Literature DB >> 23322344

NK cells from pleural effusions are potent antitumor effector cells.

Magali Terme1, Wolf Hervé Fridman, Eric Tartour.   

Abstract

Natural killer (NK) cells express a set of activating and inhibitory receptors which, after interaction with their ligands, determine whether or not the target cell will be lysed. Many studies have clearly demonstrated that NK cells have the capacity to lyse stressed cells (such as tumor or virally-infected cells). However, NK cells that infiltrate tumors usually exhibit phenotypic and functional defects. In this issue of the European Journal of Immunology, Vacca et al. [Eur. J. Immunol. 2013. 43: 550-561] show that NK cells in pleural effusions of primary and metastatic tumors of various origins are not anergic, possibly because the downregulation of activating receptors and the upregulation of inhibitory receptors does not occur, as previously reported for tumor NK cells. Another major finding of this study is the capacity of these pleural NK cells to respond to IL-2 stimulation, as the authors demonstrate that pleural NK cells stimulated by IL-2 in long-term culture acquire the capacity to lyse autologous tumor cells isolated from pleural effusions. These results support the treatment of primary or metastatic pleural tumors with IL-2 or other innovative strategies currently being developed to stimulate NK cells in cancer patients as discussed in this Commentary.
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23322344     DOI: 10.1002/eji.201243264

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

Review 1.  Impact of dietary components on NK and Treg cell function for cancer prevention.

Authors:  Young S Kim; Thomas J Sayers; Nancy H Colburn; John A Milner; Howard A Young
Journal:  Mol Carcinog       Date:  2015-04-01       Impact factor: 4.784

2.  IL15 induces a potent antitumor activity in NK cells isolated from malignant pleural effusions and overcomes the inhibitory effect of pleural fluid.

Authors:  D Croxatto; S Martini; L Chiossone; F Scordamaglia; C F Simonassi; L Moretta; M C Mingari; P Vacca
Journal:  Oncoimmunology       Date:  2017-02-17       Impact factor: 8.110

Review 3.  Trial Watch: Adoptive cell transfer for oncological indications.

Authors:  Fernando Aranda; Aitziber Buqué; Norma Bloy; Francesca Castoldi; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-05-05       Impact factor: 8.110

Review 4.  Colorectal cancer and immunity: what we know and perspectives.

Authors:  Simon Pernot; Magali Terme; Thibault Voron; Orianne Colussi; Elie Marcheteau; Eric Tartour; Julien Taieb
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

5.  Enhanced Control of Bladder-Associated Tumors Using Shrimp Anti-Lipopolysaccharide Factor (SALF) Antimicrobial Peptide as a Cancer Vaccine Adjuvant in Mice.

Authors:  Han-Ning Huang; Venugopal Rajanbabu; Chieh-Yu Pan; Yi-Lin Chan; Jyh-Yih Chen; Chang-Jer Wu
Journal:  Mar Drugs       Date:  2015-05-21       Impact factor: 5.118

6.  An allogeneic NK cell line engineered to express chimeric antigen receptors: A novel strategy of cellular immunotherapy against cancer.

Authors:  Cécile Badoual; Pierre-Louis Bastier; Hélène Roussel; Marion Mandavit; Eric Tartour
Journal:  Oncoimmunology       Date:  2013-11-14       Impact factor: 8.110

Review 7.  Classification of current anticancer immunotherapies.

Authors:  Lorenzo Galluzzi; Erika Vacchelli; José-Manuel Bravo-San Pedro; Aitziber Buqué; Laura Senovilla; Elisa Elena Baracco; Norma Bloy; Francesca Castoldi; Jean-Pierre Abastado; Patrizia Agostinis; Ron N Apte; Fernando Aranda; Maha Ayyoub; Philipp Beckhove; Jean-Yves Blay; Laura Bracci; Anne Caignard; Chiara Castelli; Federica Cavallo; Estaban Celis; Vincenzo Cerundolo; Aled Clayton; Mario P Colombo; Lisa Coussens; Madhav V Dhodapkar; Alexander M Eggermont; Douglas T Fearon; Wolf H Fridman; Jitka Fučíková; Dmitry I Gabrilovich; Jérôme Galon; Abhishek Garg; François Ghiringhelli; Giuseppe Giaccone; Eli Gilboa; Sacha Gnjatic; Axel Hoos; Anne Hosmalin; Dirk Jäger; Pawel Kalinski; Klas Kärre; Oliver Kepp; Rolf Kiessling; John M Kirkwood; Eva Klein; Alexander Knuth; Claire E Lewis; Roland Liblau; Michael T Lotze; Enrico Lugli; Jean-Pierre Mach; Fabrizio Mattei; Domenico Mavilio; Ignacio Melero; Cornelis J Melief; Elizabeth A Mittendorf; Lorenzo Moretta; Adekunke Odunsi; Hideho Okada; Anna Karolina Palucka; Marcus E Peter; Kenneth J Pienta; Angel Porgador; George C Prendergast; Gabriel A Rabinovich; Nicholas P Restifo; Naiyer Rizvi; Catherine Sautès-Fridman; Hans Schreiber; Barbara Seliger; Hiroshi Shiku; Bruno Silva-Santos; Mark J Smyth; Daniel E Speiser; Radek Spisek; Pramod K Srivastava; James E Talmadge; Eric Tartour; Sjoerd H Van Der Burg; Benoît J Van Den Eynde; Richard Vile; Hermann Wagner; Jeffrey S Weber; Theresa L Whiteside; Jedd D Wolchok; Laurence Zitvogel; Weiping Zou; Guido Kroemer
Journal:  Oncotarget       Date:  2014-12-30

Review 8.  Exploiting Human NK Cells in Tumor Therapy.

Authors:  Paola Vacca; Gabriella Pietra; Nicola Tumino; Enrico Munari; Maria Cristina Mingari; Lorenzo Moretta
Journal:  Front Immunol       Date:  2020-01-17       Impact factor: 7.561

Review 9.  Trial Watch: Adoptive cell transfer for anticancer immunotherapy.

Authors:  Fernando Aranda; Erika Vacchelli; Florine Obrist; Alexander Eggermont; Jérôme Galon; Wolf Hervé Fridman; Isabelle Cremer; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-05-01       Impact factor: 8.110

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.